Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Duodenal Adenocarcinoma: Surgical Results of 27 Patients Treated at a Single Cen...
Journal Information
Vol. 97. Issue 9.
Pages 523-530 (November 2019)
Vol. 97. Issue 9.
Pages 523-530 (November 2019)
Original article
DOI: 10.1016/j.cireng.2019.10.013
Full text access
Duodenal Adenocarcinoma: Surgical Results of 27 Patients Treated at a Single Center
Adenocarcinoma duodenal: resultados del tratamiento quirúrgico de una serie unicéntrica de 27 pacientes
Josefina López-Domíngueza, Juli Busquetsa,
Corresponding author

Corresponding author.
, Lluis Secanellaa, Nuria Peláeza, Teresa Serranob, Juan Fabregata
a Unidad de Cirugía Hepatobiliar y Pancreática, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
b Servicio de Anatomía Patológica, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Tables (5)
Table 1. Duodenal Adenocarcinoma: Results of Surgical Treatment, Details of Surgical Technique and Postoperative Morbidity.
Table 2. .Postoperative Morbidity: Comparison Between the 2 Study Groups.
Table 3. Pathologic Anatomy Results.
Table 4. Duodenal Adenocarcinoma: Surgical Treatment Results, Pathology Study and Long-term Evolution.
Table 5. Study of Risk Factors for Long-term Mortality After Surgery for Duodenal Adenocarcinoma (Hospital Universitari de Bellvitge, 1990–2017).
Show moreShow less

Duodenal adenocarcinoma is a rare malignancy. Given the rarity of the disease, there is limited data related to resection results. The objective is to analyze results at our hospital after the curative resection of duodenal adenocarcinoma (DA).

Material and methods

The variables were retrospectively collected from patients operated on between 1990 and 2017 at our hospital.


A total of 27 patients were treated. Twenty-three patients (85%) underwent pancreaticoduodenectomy, and 4 patients (15%) with tumors located in the third and fourth portions of the duodenum underwent segmental duodenal resection. The overall postoperative morbidity was 63% (17 patients). Postoperative mortality was 7% (2 patients); however, postoperative mortality related to surgery was 4% (1 patient). All patients had negative resection margins. A median of 18 lymph nodes (range, 0–38) were retrieved and evaluated, with a median of 1 involved node (range, 0–8). Median follow up was 23 (9–69.7) months. Actuarial overall survival was 62.2 (25.2–99.1) months. Actuarial disease-free survival was 49 (0–133) months.


The surgical treatment of duodenal adenocarcinoma is associated with a high morbidity, although it achieves considerable survival. Depending on the tumor location and if there is no pancreatic infiltration, segmental duodenal resection with negative margins is an alternative to cephalic pancreaticoduodenectomy.

Duodenal adenocarcinoma
Segmental duodenal resection

El adenocarcinoma de duodeno es una neoplasia poco frecuente, sobre la que existen pocas experiencias publicadas de los resultados tras su resección. El objetivo es analizar los resultados obtenidos en nuestro centro tras la resección curativa del adenocarcinoma duodenal (AD).

Material y métodos

Estudio retrospectivo de los pacientes intervenidos con resección curativa por AD entre 1990 y 2017 en nuestro hospital.


Se intervinieron 27 pacientes. En 23 casos (85%) se realizó duodenopancreatectomía cefálica (DPC) y en 4 casos (15%) con localización en 3ª-4ª porción duodenal se realizó duodenectomía segmentaria (DD). La morbilidad postoperatoria global fue del 63% (17 pacientes). La mortalidad postoperatoria global fue 7% (2 pacientes), sin embargo, la mortalidad postoperatoria relacionada con la cirugía fue de 4% (1 paciente). El estudio anatomopatológico evidenció resección con márgenes libres en todos los casos intervenidos. La mediana de adenopatías resecadas fue 18 (0 a 38), siendo 1 (0 a 8) las adenopatías afectas. Tras una mediana de seguimiento de 23 (9–69,7) meses, la supervivencia actuarial fue de 62,2 (25,2 a 99,1) meses y la supervivencia actuarial libre de enfermedad fue de 49 (0 a 133) meses.


La resección quirúrgica del adenocarcinoma duodenal comporta una elevada morbilidad postoperatoria, sin embargo, consigue una supervivencia prolongada. Dependiendo de la localización y en ausencia de infiltración pancreática, la duodenectomía segmentaria con márgenes libres es una alternativa a la duodenopancreatectomía cefálica.

Palabras clave:
Adenocarcinoma duodenal
Duodenopancreatectomía cefálica
Full Text

Duodenal adenocarcinoma (DA) is an uncommon neoplasm, even though the duodenum is the most common location for adenocarcinomas of the small intestine.1–4 The majority of DA are located in the second part of the duodenum (D2), followed by the 3rd and 4th parts (D3-D4), while the first part is very rarely affected.3 The symptoms are nonspecific, such as abdominal pain, nausea, vomiting, asthenia or weight loss, and abdominal pain is the most frequent. In cases of advanced disease, jaundice, intestinal obstruction or anemia may occur. Due to the non-specificity of the symptoms, the diagnosis of the disease is usually late.

The suspected diagnosis is confirmed by upper gastrointestinal endoscopy with biopsy. Multislice abdominal computed tomography scan is essential for the extension study.5 The treatment of choice is surgical resection. Regarding the technique, initially pancreaticoduodenectomy (PD) was considered standard treatment.6 Afterwards, segmental resection or surgical duodenectomy was considered a valid option for this type of tumors, (DD), depending on the location, resection margins, surgical lymphadenectomy.4,7–9 However, there is no consensus in this regard, some authors support PD|as, the technique of choice in all cases.10,11 The objective of this study is to analyze the results obtained at our hospital after the curative resection of DA using PD, DD.


Between 1990 and 2017, we retrospectively registered patients who underwent surgery with curative intent for DA at the Hospital Universitari de Bellvitge (Barcelona, Spain). Demographic, clinical, surgical and pathological variables were collected, as well as data regarding the postoperative and long-term evolution. The inclusion period ended in March 2017. The patients were monitored in outpatient surgery consultations, and follow-up was completed in March 2018.

Preoperative Study

All patients were studied using upper gastrointestinal endoscopy with biopsy and computed tomography. The presence of distant metastases and arterial invasion (superior mesenteric artery, hepatic artery or celiac trunk) were defined as unresectable criteria. Regarding venous involvement, no resections were performed in patients with large duodenal tumors that would involve obliteration of the superior mesenteric vein. Neither advanced patient age nor tumor size were contraindications for surgery.

Surgical Technique and Pathological Study

The surgical techniques used were PD in those cases in which the tumor affected D2 or there was invasion of the pancreas, and DD for patients with D3-D4 involvement. In tumors that were treated with PD due to their location, standard locoregional lymphadenectomy was performed (peripancreatic lymphadenopathies, hepatic hilum and right margin of the superior mesenteric artery). The pathological study analyzed the degree of tumor differentiation, tumor size, involvement of resection margins, number of affected and resected lymphadenopathies and established the TNM stage (7th Edition of the American Joint Committee on Cancer [AJCC] Staging system for small bowel adenocarcinoma12). In both the DD and PD, the intestinal margin was considered a resection margin. The lymph node ratio was defined as the number of lymph nodes affected over the total number of resected lymph nodes.

Postoperative Morbidity

Postoperative morbidity was registered in accordance with the Clavien-Dindo classification.13 Postoperative mortality was defined as death that occurred during hospitalization or up to 90 days after surgery. Delayed gastric emptying (DGE) was defined as the inability to tolerate oral intake after the first postoperative week, following the definition of the International Study Group of Pancreatic Surgery (ISGPS).14 Pancreatic fistula was defined as discharge of fluid through the drain tubes that was rich in amylase (amylase ×3 compared to normal blood levels) after postoperative day 3, applying the ISGPS classification.15 All patients were followed by a member of the surgical team after hospital discharge.

Statistical Analysis

The Stata v.13® statistical package was used. Initially, a descriptive analysis of the series was performed using measures of central tendency (median) and dispersion (interquartile range and range) for quantitative variables. Next, the series was divided into 2 study groups according to the technique used, PD and DD, and the 2 groups were compared using Fisher’s test for qualitative variables and the Mann–Whitney U for quantitative variables. A P level <.05 was considered statistically significant. Actuarial survival rates (global and disease-free) were calculated for each study group using the Kaplan–Meier test. A study of risk factors for mortality and recurrence was conducted with univariate Cox regression models. For the multivariate analysis, we selected the significant variables from the univariate study, the study variable (surgical technique), as well as the demographic variables (age and sex).


During the study period, 27 patients were treated surgically. In 23 cases (85%), PD was conducted, and in 4 cases (15%) DD was performed (Table 1). The median patient age was 63.4 (50.8–74.1) years, with no significant differences between the 2 groups. The patients included 13 women (48%): 11 in the PD group (48%) and 2 in the DD group (50%).

Table 1.

Duodenal Adenocarcinoma: Results of Surgical Treatment, Details of Surgical Technique and Postoperative Morbidity.

Age  Sex  Surgical Technique  Morbidity  Clavien-Dindo  Postoperative Hospital Stay 
74  PD  DGE, pancreatic fistula(B), SSI  II  21 
45  PD  Pancreatic fistula(A)  II  29 
68  PD  Pancreatic fistula(B), hemorrhage, SSI  IIIa  64 
82  DD  Infectious complications (SSI, respiratory, urinary, intra-abdominal collection), exitus  40 
75  PD  Pancreatic fistula(A), intra-abdominal collection  IIIa 
61  PD  DGE, pancreatic fistula(B), Intra-abdominal collection  IIIa  37 
46  DD  DGE, intra-abdominal collection  II 
74  PD  ------  II  15 
63  PD  ------  II 
10  43  PD  ------  II  11 
11  74  DD  ------ 
12  76  PD  ------  II  22 
13  51  DD  DGE, intra-abdominal collection  IIIa  47 
14  30  PD  DGE, intra-abdominal collection  IIIa  28 
15  65  PD  Pancreatic fistula(B), intra-abdominal collection  IIIa  29 
16  83  PD  Pancreatic fistula(B), SSI, intra-abdominal collection  IIIa  30 
17  42  PD  ------  14 
18  69  PD  G-J dehiscence, re-operation, exitus 
19  37  PD  DGE  II  36 
20  50  PD  DGE  II  24 
21  63  PD  UTI  II  19 
22  60  PD  DGE  II  23 
23  50  PD  DGE  II  24 
24  67  PD  DGE, SSI  II  25 
25  63  PD  ------  11 
26  65  PD  ------  20 
27  60  PD  ------ 

DD: duodenectomy; PD: pancreaticoduodenectomy; F: female; SSI: surgical site infection; UTI: urinary tract infection; M: male; DGE: delayed gastric emptying.

Morbidity according to Clavien-Dindo classification30; hospital stay in days.

Postoperative Results

The overall postoperative morbidity was 63% (17 patients). Three patients (11%) presented a complication higher than IIIa of the Clavien–Dindo classification.13 When we analyzed the complications in terms of the technique performed, postoperative morbidity was 65% after PD (15 out of 23 patients) and 75% after DD (3 out of 4 patients), with no statistically significant differences (Table 2). The most frequent complication in the entire series was DGE, which was observed in 37% (10 patients), with no statistically significant differences between the two techniques. Septic complications were seen in 44% (12 patients). Finally, the pancreatic fistula rate after PD was 30% (7 patients: 2 type A and 5 type B). The median postoperative stay was 22 (11–29) days, which was similar in both groups. Out of the total of the series, one patient (4%) had to be reoperated due to dehiscence of the gastrojejunal anastomosis, requiring sutures and surgical drain placement. Postoperative mortality was 7% (2 patients). One patient of the PD group died due to multiple organ failure after being reoperated for anastomotic dehiscence. Another patient of the DD group died 40 days after surgery due to hyperammonemic encephalopathy and respiratory failure, without having presented any intra-abdominal complications. There were no statistically significant differences in postoperative mortality between the two study groups (P = .279) (Table 2).

Table 2.

.Postoperative Morbidity: Comparison Between the 2 Study Groups.

Variables  Total (n = 27)  PD (n = 23; 85%)  DD (n = 4; 15%)  P Value 
Complications, n (%)  18 (67%)  15 (65)  3 (75%)  .702 
DGE, n (%)  10 (37)  8 (35)  2 (50)  .613 
PF, n (%)    7 (30)     
Hemorrhage, n (%)  1 (4)  1 (4) 
Infectious, n (%)  12 (44)  9 (31)  3 (75)  .294 
Incisional, n (%)  5 (18)  4 (17)  1 (25) 
Respiratory, n (%)  1 (4)  1 (25)  .148 
Urinary, n (%)  2 (7)  1 (5)  1 (25)  .279 
Catheter, n (%)  1 (4)  1 (25)  .148 
IA abscess, n (%)  8 (30)  5 (22)  3 (75)  .065 
Re-operation, n (%)  1 (4)  1 (4) 
Postoperative death, n (%)  2 (7)  1 (4)  1 (25)  .279 

DD: duodenectomy; PD: pancreaticoduodenectomy; IA: intra-abdominal; PF: pancreatic fistula; DGE: delayed gastric emptying.

Pathological Study

The pathological study showed that the majority of patients were pT4 (15 patients, 55%), with pN1 lymph node involvement (15 patients, 55%) according to the TNM classification (7th edition of the AJCC12) (Tables 3 and 4) (Fig. 1). In 4 patients, the pathological study could not be fully recovered. The degree of tumor differentiation most frequently registered was moderately differentiated (41%). Tumor size was greater than 30 mm in 59% (16 cases). In all cases, resection was performed with free margins. The median number of resected lymphadenopathies was 18 (0–38), including 22 in the PD group (4–38) and 12.5 (0–15) in the DD group, which were statistically significant differences (P = .016).

Table 3.

Pathologic Anatomy Results.

    Total (n = 27)  PD (n = 23; 85%)  DD (n = 4; 15%) 
pT1  1 (4%)  1 (4%)  0 (0%) 
  pT2  2 (7%)  2 (9%)  0 (0%) 
  pT3  9 (33%)  6 (26%)  3 (75%) 
  pT4  15 (55%)  14 (61%)  1 (25%) 
pN0  9 (33%)  6 (26%)  3 (75%) 
  pN1  15 (55%)  14 (61%)  1 (25%) 
  pN2  3 (11%)  3 (13%)  0 (0%) 
Tumor differentiation grade
Well-differentiated    3 (11%)  2 (9%)  1 (25%) 
Moderately-differentiated    11 (41%)  10 (43%)  1 (25%) 
Undifferentiated    9 (33%)  8 (35%)  1 (25%) 
Not registered    4 (15%)  3 (13%)  1 (25%) 
Resected (median, range)    18 (0 to 38)  22 (4 to 38)  12.5 (0 to 15) 
Affected (median, range)    1 (0 to 8)  2 (0 to 8)  0 (0 to 1) 
Ratio (median, range)    8.83 (0 to 43.8)  9.1 (0 to 43.8)  0 (0 to 7.7) 
Involved surgical margins    0 (0%)  0 (0%)  0 (0%) 
Table 4.

Duodenal Adenocarcinoma: Surgical Treatment Results, Pathology Study and Long-term Evolution.

NR  Surgical Technique  Differentiation Grade  TNM  Tumor Size (mm)  Affected/resected LA  Recurrence  DFS (Months)  Survival (Months)  Current State 
PD  Moderate  pT4N2  30  4/35  No  9.1  9.1  Living 
PD  Moderate  pT4N1  35  2/20  Yes  20.3  20.8  Living 
PD  Well-diff.  pT3N0  48  0/12  No  23.6  23.6  Living 
DD  Not registered  pT3N0  65    –    1.3  Exitus (post-op) 
PD  Undifferentiated  pT4N2  60  4/17  Yes  15.8  17.7  Living 
PD  Well-diff.  pT3N1  20  1/24  No  42.9  42.9  Living 
DD  Moderate  pT3N0  30  0/15  No  46.9  46.9  Living 
PD  Moderate  pT4N2  70  7/26  Yes  5.6  10.1  Exitus 
PD  Undifferentiated  pT2N1  45  1/ 4  No  66.2  66.2  Exitus 
10  PD  Not registered  pT3N1  25  2/22  No  58.1  58.1  Exitus 
11  DD  Well-diff.  pT4N0  0/12  No  70.7  70.7  Living 
12  PD  Undifferentiated  pT3N1  40  3/26  Yes  3.06  3.4  Exitus 
13  DD  Undifferentiated  pT3N1  70  1/13  No  92.9  92.9  Living 
14  PD  Undifferentiated  pT4N1  80  3/35  Yes  11.9  35.5  Exitus 
15  PD  Undifferentiated  pT1N0  25  0/18  No  99.6  99.6  Living 
16  PD  Moderate  pT4N0  28  0/17  No  94.3  94.3  Exitus 
17  PD  Moderate  pT3N0  40  0/29  No  124.9  124.9  Living 
18  PD  Moderate  pT4N1  25  7/16  –    0.2  Exitus (post-op) 
19  PD  Undifferentiated  pT4N1  40  1/12  Yes  123.4  180.4  Living 
20  PD  Moderate  pT4N1  50  8/26  Yes  13.7  16.4  Exitus 
21  PD  Moderate  pT4N1  30  5/38  Yes  10.6  13  Exitus 
22  PD  Undifferentiated  pT4N1  70  2/22  Yes  3.7  7.5  Exitus 
23  PD  Undifferentiated  pT4N1  45  3/15  Yes  5.06  Exitus 
24  PD  Moderate  pT3N1  55  2/27  Yes  50.6  63.1  Exitus 
25  PD  Moderate  pT4N0  0/14  No  239.5  239.5  Living 
26  PD  Not registered  pT4N1      Yes  4.6  5.1  Exitus 
27  PD  Not registered  pT2N0  12    Not registered  12.4  13.2  Exitus 

Well-diff.: well-differentiated; DD: duodenectomy; PD: pancreaticoduodenectomy; DFS: disease-free survival, LA: lymphadenopathies.

Fig. 1.

Pathological study of the surgical resection specimens after duodenectomy (A) and pancreaticoduodenectomy (B).

Survival and Follow-up

The median follow-up was 23 (9–69.7) months. During this period, 15 (55%) patients died (14 PD and 1 DD) and 12 (44%) patients were alive (9 PD and 3 DD). The overall 1, 3 and 5-year survival rates in PD were 74, 54 and 47%, respectively. In DD, the 1, 3 and 5-years rates were all 75%. No statistically significant differences were found between the two techniques (Fig. 2).

Fig. 2.

Survival after resection for duodenal adenocarcinoma, Kaplan–Meier analysis (log-rank, P = .327). Dashed line: duodenectomy group results. Solid line: pancreaticoduodenectomy group results (Hospital Universitari de Bellvitge. 1990–2017).



The median overall survival was 62.2 (25.2–99.1) months. Out of all the variables analyzed in the univariate study, only the lymph node ratio greater than 0.20 was a risk factor for long-term mortality (P = .009), a result that was confirmed by the multivariate analysis (Table 5).

Table 5.

Study of Risk Factors for Long-term Mortality After Surgery for Duodenal Adenocarcinoma (Hospital Universitari de Bellvitge, 1990–2017).

Variable  UnivariateMultivariate
  HR (95% CI)  P  HR (95% CI)  P 
Duodenectomy surgical technique  0.38 (0.05 to 2.88)  .346  0.52 (0.06 to 4.28)  .542 
Age > 70  1.37 (0.43 to 4.33)  .589  1.91 (0.31 to 11.9)  .485 
Females  0.81 (0.29 to 2.25)  .683  1.16 (0.31 to 4.44)  .824 
ASA classification    .653     
ASA II  0.64 (0.16 to 2.47)  .514     
ASA III  1.22 (0.39 to 3.88)  .731     
Transfusion of more than 1 unit of packed red blood cells during post-op (first 48)  1.45 (0.49 to 4.32)  .502     
Presence of post-op complications  0.88 (0.31 to 2.50)  .813     
Tumor size greater than 30mm  1.70 (0.58 to 5.00)  .337     
Tumor grade differentiation         
G2  0.74 (0.21 to 2.70)  .654     
G3  0.73 (.19 to 2.78)  .643     
Lymph node ratio N > 0.20  4.23 (1.44 to 12.4)  .009  4.87 (1.08 to 21.9)  .039 

ASA: American Society of Anesthesiologists; CI: confidence interval; HR: hazard ratio.

Out of the total series, 13 patients (48%) had recurrence, 10 of whom died and 3 are still alive. All these patients had been treated by PD. The 1, 3 and 5-year disease-free actuarial survival rates were 71, 55 and 49%, respectively. The median disease-free survival was 49 (0–133) months (Table 4). None of the variables analyzed was a risk factor for long-term recurrence in the univariate or multivariate study.


There are few publications in the literature analyzing the surgical results of DA.16 The choice of surgical technique (PD vs. DD) is based on the location of the tumor and the presence of pancreatic infiltration. Classically, the technique of choice for DA was PD6 because it was considered the only method that could offer acceptable cancer outcomes. Subsequently, publications emerged with comparable results in terms of survival for DD and PD.4,17,18 Even so, there is still controversy about which oncological approach is the most appropriate, and there are authors who currently defend PD as the best treatment.11 In our experience, morbidity after resection for DA is 65% in the PD group and 75% in the DD group, with no statistically significant differences, which are results similar to other authors.4,19 However, several groups19,20 defend DD as a technique with similar postoperative morbidity. The postoperative mortality in our series was 7%, which is similar to publications by others.1,4,19,21–23 Like our results, other authors have compared postoperative mortality between PD and DD, finding no statistically significant differences.4,19 Postoperative mortality in our DD group due to adenocarcinoma was high (1 out of 4 patients); however, the cause of death of the patient in this group was not related to the surgical technique. When we reviewed our experience in DD for different indications, we have found a lower mortality rate (4%).24,25

Several prognostic factors have been proven to influence DA survival. Some of them refer to patient age,23,26 sex,27 tumor differentiation10,26 and tumor stage.26 In the pathological study, the variables related with the prognosis of DA, so far, are the involvement of the resection margin,1,4,10,18,21 number of resected lymphadenopathies, involvement of resected lymphadenopathies and the lymph node ratio.4,7,21,22,26,28,29 In our series, the involvement of the resection margin was zero in both study groups, with an actuarial 5-year survival after resection of 52%. Several authors have demonstrated that survival is affected if there is involvement of the resection margins. For instance, Sohn et al.10 published a 5-year survival rate of 58% in the case of R0 and 0% in the case of R1. Similar values are described by Poultsides et al.21 with a 5-year survival of 55% in R0 and 0% in R1.

The importance of lymphadenectomy is also well documented in the literature, despite there being no consensus on the number of nodes to resect.4,7,21,22,26 The AJCC recommends resecting a minimum of 6 nodes in DA surgery, although there are authors who believe that this number should be greater for better staging.3,21,28 Sarela et al.23 found statistically significant differences in 5-year survival between pN0 and pN+ patients when the number of resected nodes was equal to or greater than 15. In contrast, if the number of resected nodes was less than 15, the 5-year survival results were similar between both groups. In our study, we registered a greater number of nodes after PD compared to DD (22 vs. 12.5; P = .016), although this did not imply better survival. Other authors demonstrated similar results to our experience. Sakamoto et al.11 published a series with an average of 26 resected lymph nodes in the PD group vs. 14 nodes in the DD group (P = .001), with no differences in survival between the two groups. Along the same lines, Cloyd et al.26 showed results of a lymphadenectomy with a greater number of lymph nodes in the PD compared to DD (11 ± 8.9 vs. 6.8 ± 7.8; P < .0001), with no changes in long-term survival between the two groups. Several authors have shown that the lymph node ratio (affected nodes/resected nodes) is the most appropriate prognostic predictor.21,26,28,29 In our series, the lymph node ratio was the only variable that was proven to be a prognostic factor for long-term mortality. Finally, we have not observed differences in survival when comparing the 2 surgical techniques (PD and DD).4,11,26 In our series, the overall survival after resection for DA was 62.2 months and 52% after 5. These results are slightly higher than other published reports, with a survival between 30–45 months4,19,22,27 and a 5-year survival of 23%–48%.1,4,19,21,22

Being a rare entity, the number of patients in our study is low, despite a prolonged period of study. Therefore, it is difficult to draw conclusions, which is one of the limitations of this study. However, after analyzing our experience and that of other authors, we believe that both surgical options can be considered, depending on the tumor location and the degree of pancreatic involvement.


Surgical resection of DA involves high postoperative morbidity, even though it is able to prolong survival. Depending on the location and in the absence of pancreatic invasion, segmental DD with free margins is an alternative to PD.

Conflict of Interests

The authors have no conflict of interests to declare.

WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
A. Tocchi, G. Mazzoni, F. Puma, et al.
Adenocarcinoma of the third and fourth portions of the duodenum: results of surgical treatment.
Arch Surg, 138 (2003), pp. 80-85
B.S. Dabaja, D. Suki, B. Pro, M. Bonnen, J. Ajani.
Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.
Cancer, 101 (2004), pp. 518-526
J.F. Gibbs.
Duodenal adenocarcinoma: is total lymph node sampling predictive of outcome.
Ann Surg Oncol, 11 (2004), pp. 354-355
I.G. Kaklamanos, O.F. Bathe, D. Franceschi, C. Camarda, J. Levi, A.S. Livingstone.
Extent of resection in the management of duodenal adenocarcinoma.
Am J Surg, 179 (2000), pp. 37-41
J.M. Cloyd, E. George, B.C. Visser.
Duodenal adenocarcinoma: advances in diagnosis and surgical management.
World J Gastrointest Surg, 8 (2016), pp. 212-221
William M. Moss, P. Michael McCart, George Juler, Don R. Miller, C. Irvine.
Primary adenocarcinoma of the duodenum.
Arch Surg, 108 (1974), pp. 805-807
D.R. Joesting, R.W. Beart, J.A. van Heerden, L.H. Weiland.
Improving survival in adenocarcinoma of the duodenum.
Am J Surg, 141 (1981), pp. 228-231
J.A. Lowell, R.L. Rossi, J.L. Munson, J.W. Braasch.
Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection.
J.G. Barnes, L. Romero, K.R. Hess, S.A. Curley.
Primary adenocarcinoma of the duodenum: management and survival in 67 patients.
Ann Surg Oncol, 1 (1994), pp. 73-78
T.A. Sohn, K.D. Lillemoe, J.L. Cameron, et al.
Adenocarcinoma of the duodenum: factors influencing long-term survival.
J Gastrointest Surg, 2 (1998), pp. 79-87
T. Sakamoto, A. Saiura, Y. Ono, et al.
Optimal lymphadenectomy for duodenal adenocarcinoma: does the number alone matter?.
Ann Surg Oncol, 24 (2017), pp. 3368-3375
S.B. Edge, C.C. Compton.
The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
Ann Surg Oncol, 17 (2010), pp. 1471-1474
P.A. Clavien, J. Barkun, M.L. De Oliveira, et al.
The Clavien–Dindo classification of surgical complications: five-year experience.
Ann Surg, 250 (2009), pp. 187-196
M.N. Wente, C. Bassi, C. Dervenis, et al.
Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS).
Surgery, 142 (2007), pp. 761-768
C. Bassi, C. Dervenis, G. Butturini, et al.
Postoperative pancreatic fistula: an international study group (ISGPF) definition.
J.M. Ramia, J. Villar, A. Palomeque, et al.
Adenocarcinoma de duodeno.
F. Sista, et al.
Adenocarcinoma of the third duodenal portion: Case report and review of literature.
World J Gastrointest Surg, 4 (2012), pp. 23-26
F.G. Bakaeen, M.M. Murr, M.G. Sarr, et al.
What prognostic factors are important in duodenal adenocarcinoma?.
Arch Surg, 135 (2000), pp. 635-642
L. Solaini, N.B. Jamieson, M. Metcalfe, et al.
Outcome after surgical resection for duodenal adenocarcinoma in the UK.
Br J Surg, 102 (2015), pp. 676-681
F.J. García-Molina, F. Mateo-Vallejo, D. Franco-Osorio Jde, J.L. Esteban-Ramos, I. Rivero-Henández.
Surgical approach for tumours of the third and fourth part of the duodenum. Distal pancreas-sparing duodenectomy.
Int J Surg, 18 (2015), pp. 143-148
G.A. Poultsides, L.C. Huang, J.L. Cameron, et al.
Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment.
Ann Surg Oncol, 19 (2012), pp. 1928-1935
H.G. Lee, D.D. You, K.Y. Paik, J.S. Heo, S.H. Choi, D.W. Choi.
Prognostic factors for primary duodenal adenocarcinoma.
World J Surg, 32 (2008), pp. 2246-2252
A.I. Sarela, M.F. Brennan, M.S. Karpeh, D. Klimstra, K.C.P. Conlon.
Adenocarcinoma of the duodenum: importance of accurate lymph node staging and similarity in outcome to gastric cancer.
Ann Surg Oncol, 11 (2004), pp. 380-386
J.M. Cloyd, J.A. Norton, B.C. Visser, G.A. Poultsides.
Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases.
Ann Surg Oncol, 22 (2015), pp. 573-580
A. González Castillo, J. Busquets, N. Peláez, et al.
Duodenectomía parcial con preservación pancreática, una opción quirúrgica: indicaciones y resultados.
30 Congreso Nacional de Cirugía,
J. Lopez Domínguez, N. Peláez, J. Busquets, L. Secanella, T. Serrano, J. Fabregat.
Resultados del tratamiento quirúrgico del adenocarcinoma duodenal.
XXXI Congreso Nacional de Cirugía,
T. Oyasiji, J. Alosi, W. Tan, C. Wilfong, N. Wilkinson.
Duodenal adenocarcinoma: profile and predictors of survival outcomes.
Am Surg, 81 (2015), pp. 1125-1133
M.J. Overman, C.Y. Hu, R.A. Wolff, G.J. Chang.
Prognostic value of lymph node evaluation in small bowel adenocarcinoma: Analysis of the surveillance, epidemiology, and end results database.
Cancer, 116 (2010), pp. 5374-5382
T.B. Tran, M. Qadan, M.M. Dua, J.A. Norton, G.A. Poultsides, B.C. Visser.
Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma.
Surg (United States), 158 (2015), pp. 486-492
D. Dindo, N. Demartines, P.A. Clavien.
Classification of surgical complications.

Please cite this article as: López-Domínguez J, Busquets J, Secanella L, Peláez N, Serrano T, Fabregat J. Adenocarcinoma duodenal: resultados del tratamiento quirúrgico de una serie unicéntrica de 27 pacientes Cir Esp. 2019;97:523–530.

Copyright © 2019. AEC
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos